Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...
St. Michael's Hospital, Toronto, Ontario, Canada
UT Southwestern Medical Center, Dallas, Texas, United States
University of Copenhagen, Copenhagen, Denmark
The Catholic University of Korea, Seoul, St.Mary's Hospital, Seoul, Korea, Republic of
University of California at Los Angeles, Los Angeles, California, United States
Boston Children's Hospital, Boston, Massachusetts, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Children's Memorial Health Institute, Neurology and Epileptology, Warsaw, Poland
Medical University of Warsaw, Department of Pediatric Neurology, Warsaw, Poland
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
University of Chicago, Chicago, Illinois, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.